DNA adducts as exposure biomarkers and indicators of cancer risk

Environmental Health Perspectives

Volumn 105, Issue SUPPL. 4, 1997, Pages 907-912

  Poirier, Miriam C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Carcinogen; DNA binding; Dosimetry; Environment; Human

Indexed keywords

AFLATOXIN; ANTINEOPLASTIC AGENT; ANTISERUM; AROMATIC AMINE; BIOLOGICAL MARKER; CARCINOGEN; HETEROCYCLIC AMINE; MALONALDEHYDE; NITROSAMINE; POLYCYCLIC AROMATIC HYDROCARBON; STYRENE;

BLOOD CELL; CANCER RISK; CHINA; CONFERENCE PAPER; DNA ADDUCT; DNA BINDING; DOCUMENTATION; DOSE RESPONSE; DOSIMETRY; ENVIRONMENTAL EXPOSURE; FIRE FIGHTER; FOOD CONTAMINATION; HUMAN; INSTRUMENTATION; ISOTOPE LABELING; LIVER CELL CARCINOMA; MEAT; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; UNITED STATES; URINARY EXCRETION;

EID: 0030819024     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.97105s4907     Document Type: Conference Paper

References (97)

1. Beland FA, Poirier MC. DNA adducts and carcinogenesis. In: Pathobiology of Neoplasia (Sirica AE, ed). New York:Plenum Press, 1989;57-80.
2. Weston A, Poirier MC. Development of methods for chemical carcinogen-DNA adduct determination in humans. In: Handbook of Carcinogen Testing. 2nd ed. (Milman HA, Weisburger EC, eds). Park Ridge, NJ: Plenum Publications, 1994;672-700.
3. Perera FP, Weinstein IB. Molecular epidemiology and carcinogen-DNA adduct detection: new approaches to studies of human cancer causation. J Chronic Dis 35:581-600 (1982).
4. Poirier MC, Beland FA. DNA adduct measurements and tumor incidence during chronic carcinogen exposure in animal models: implications for DNA adduct-based human cancer risk assessment. Chem Res Toxicol 5:749-755 (1992).
5. Harris CC. Chemical and physical carcinogenesis: advances and perspectives for the 1990s. Cancer Res 51:5023s-5044s (1991).
6. Poirier MC, Gupta-Burt S, Litterst CL, Reed E. Detection of cisplatin-DNA adducts in humans. In: Immunoassays for Monitoring Human Exposure to Toxic Chemicals (Vanderlaan M, ed). Washington:American Chemical Society, 1990; 300-307.
7. Terheggen PM, Dijkman R, Begg AC, Dubbelman R, Floot BG, Hart AA, den Engelse L. Monitoring of interaction products of cis-diamminedichloro-platinum(II) and cis-diammine(1,1-cyclobutane-dicarboxylato)platinum(II) with DNA in cells from platinum-treated cancer patients. Cancer Res 48:5597-5603 (1988).
8. 1-DNA adducts formed in vivo. Cancer Res 48:6328-6331 (1988).
9. 32P-postlabeling test for structurally diverse DNA adducts. Carcinogenesis 7:1543-1551 (1986).
10. 32P-postlabeling assay. Carcinogenesis 13:1053-1074 (1992).
11. Weston A, Bowman ED, Manchester DK, Harris CC. Fluorescence detection of lesions in DNA. In: DNA Damage and Repair in Human Tissues (Sutherland BM, Woodhead AD, eds). New York:Plenum Press, 1990;63-81.
12. Shuker DEG, Prevost V, Friesen MD, Lin D, Ohshima H, Bartsch H. Urinary markers for measuring exposure to endogenous and exogenous alkylating agents and precursors. Environ Health Perspect 99:33-37 (1993).
13. Reed E, Sauerhoff S, Poirier MC. Quantitation of platinum-DNA binding after therapeutic levels of drug exposure. Atomic Spectrosc 9:93-95 (1988).
14. Reed E, Ozols RF, Tarone R, Yuspa SH, Poirier MC. The measurement of cisplatin-DNA adduct levels in testicular cancer patients. Carcinogenesis 9:1909-1911 (1988).
15. Floyd RA, Watson JJ, Wong PK, Altmiller DH, Rickard RC. Hydroxyl free radical adduct of deoxyguanosine: sensitive detection and mechanisms of formation. Free Radic Res Commun 1:163-172 (1993).
16. Weston A. Physical methods for the detection of carcinogen-DNA adducts in humans. Mutat Res 288:19-29 (1993).
17. Poirier MC. Antibodies to carcinogen-DNA adducts. J Natl Cancer Inst 67:515-519 (1981).
18. Poirier MC. The use of carcinogen-DNA adduct antisera for quantitation and localization of genomic damage in animal models and the human population. Environ Mol Mutagen 6:879-887 (1984).
19. 6-ethyldeoxyguanosine in DNA exposed to the carcinogen ethylnitrosourea in vivo or in vitro. Z Naturforsch 33:897-901 (1978).
20. Leng M, Sage E, Fuchs RP, Duane MP. Antibodies to DNA modified by the carcinogen N-acetoxy-N-2-acetylaminofluorene. FEBS Lett 92:207-210 (1978).
21. Strickland PT, Boyle JM. Immunoassay of carcinogen-modified DNA. Prog Nucleic Acid Res Mol Biol 31:1-58 (1984).
22. Phillips DH. Modern methods of DNA adduct determination. In: Handbook of Experimental Pharmacology, Vol 94/I (Cooper CS, Grover PL, eds). Berlin:Springer-Verlag 1990;503-546.
23. Santella RM, Yang XY, Hsieh LL, Young TL. Immunologic methods for the detection of carcinogen adducts in humans. Prog Clin Biol Res 340C:247-257 (1990).
24. Poirier MC, Yuspa SH, Weinstein IB, Blobstein S. Detection of carcinogen-DNA adducts by radioimmunoassay. Nature 270:186-188 (1977).
25. Poirier MC, Weston A. DNA adduct determination in humans. Prog Clin Biol Res 372:205-218 (1991).
26. Santella RM, Hsieh LL, Lin CD, Viet S, Weinstein IB. Quantitation of exposure to benzo[a]pyrene with monoclonal antibodies. Environ Health Perspect 62:95-99 (1985).
27. Poirier MC. Development of immunoassays for the detection of carcinogen-DNA adduces. In: Molecular Dosimetry and Human Cancer (Skipper PL, Groopman JD, eds). Boca Raton, FL:CRC Press, 1991;211-229.
28. 6-methyldeoxyguanosine in oesophageal DNA among individuals at high risk of oesophageal cancer. Int J Cancer 36:661-665 (1985).
29. 4-ethylthymine in liver DNA of individuals with or without malignant tumors. Cancer Res 49:93-97 (1989).
30. 32P-postlabeling assay. Mutat Res 288:5-18 (1993).
31. 32P-postlabeling and nucleotide chromatographic analysis. Cancer Res 48:2156-2161 (1988).
32. 7-methyldeoxyguanosine. Cancer Res 50:6580-6584 (1990).
33. 32P-postlabeling assay. Carcinogenesis 14:545-550 (1993).
34. Stillwell WG, Glogowski J, Xu HX, Wishnok JS, Zavala D, Montes G, Correa P, Tannenbaum SR. Urinary excretion of nitrate, N-nitrosoproline, 3-methyladenine, and 7-methylguanine in a Colombian population at high risk for stomach cancer. Cancer Res 51:190-194 (1991).
35. 32P postlabeling, and immunoprecipitation. Cancer Res 52:5307-5312 (1992).
36. 1 formamidopyrimidine adducts in human hepatocarcinogenesis: a preliminary report. Gastroenterology 97:1281-1287 (1989).
37. Groopman JD, Donahue PR, Zhu JQ, Chen JS, Wogan GN. Aflatoxin metabolism in humans: detection of metabolites and nucleic acid adducts in urine by affinity chromatography. Proc Natl Acad Sci USA 82:6492-6496 (1985).
38. Sun TT, Wu SM, Wu YY, Chu YR. Measurement of individual aflatoxin exposure among people having different risk to primary hepatocellular carcinoma. In: Diet, Nutrition and Cancer (Hyaishi Y, Nagao M, Sugimura T, Takayama S, Tomatis L, Wattenberg LW, Wogan GN, eds). Tokyo:Japan Scientific Society Press, 1986;225-235.
39. Talaska G, al-Juburi AZ, Kadlubar FF. Smoking related carcinogen-DNA adducts in biopsy samples of human urinary bladder: identification of N-(deoxyguanosin-8-yl)-4-aminobiphenyl as a major adduct. Proc Natl Acad Sci USA 88:5350-5354 (1991).
40. Roberts DW, Benson RW, Groopman JD, Flammang TJ, Nagle WA, Moss AJ, Kadlubar FF. Immunochemical quantitation of DNA adducts derived from the human bladder carcinogen 4-aminobiphenyl. Cancer Res 48:6336-6342 (1988).
41. 6-alkylguanine-DNA alkyltransferase activities in gastric mucosa and circulating lymphocytes. Carcinogenesis 11:431-436 (1990).
42. Haugen A, Becher G, Benestad C, Vahakangas K, Trivers GE, Newman MJ, Harris CC. Determination of polycyclic aromatic hydrocarbons in the urine, benzo[a]pyrene diol epoxide-DNA adducts in lymphocyte DNA, and antibodies to the adducts in sera from coke oven workers exposed to measured amounts of polycyclic aromatic hydrocarbons in the work atmosphere. Cancer Res 46:4178-4183 (1986).
43. van Schooten FJ, Hillebrand MJ, van Leeuwen FE, Lutgerink JT, van Zandwijk N, Jansen HM, Kriek E. Polycyclic aromatic hydrocarbon-DNA adducts in lung tissue from lung cancer patients. Carcinogenesis 11:1677-1681 (1990).
44. Perera FP, Hemminki K, Young TL, Brenner D, Kelly G, Santella RM. Detection of polycyclic aromatic hydrocarbon-DNA adducts in white blood cells of foundry workers. Cancer Res 48:2288-2291 (1988).
45. Poirier MC, Egorin MJ, Fichtinger-Schepman AM, Yuspa SH, Reed E. DNA adducts of cisplatin and carboplatin in tissues of cancer patients. In: Methods for Detecting DNA Damaging Agents in Humans: Applications in Cancer Epidemiology and Prevention (Bartsch H, Hemminki K, O'Neill IK, eds). IARC Scientific Publications No 89. Lyon:International Agency for Research on Cancer, 1988;313-320.
46. 6-methylguanine in human blood leukocyte DNA during exposure to procarbazine and its relationships with dose and repair. Cancer Res 50:2759-2764 (1990).
47. 7-methylguanine in DNA of white blood cells from cancer patients treated with dacarbazine. Carcinogenesis 13:1257-1259 (1992).
48. Paleologo M, van Schooten FJ, Pavanello S, Kriek E, Zordan M, Clonfero E, Bezze C, Levis AG. Detection of benzo[a]pyrenediol-epoxide-DNA adducts in white blood cells of psoriatic patients treated with coal tar. Mutat Res 281:11-16 (1992).
49. Santella RM, Yang XY, DeLeo VA, Gasparro FP. Detection and quantification of 8-methoxypsoralen-DNA adducts. In: Methods for Detecting DNA Damaging Agents in Humans: Applications in Cancer Epidemiology and Prevention (Bartsch H, Hemminki K, O'Neill IK, eds). IARC Scientific Publications No 89. Lyon:International Agency for Research on Cancer, 1988;333-340.
50. Degan P, Shigenaga MK, Park EM, Alperin PE, Ames BN. Immunoaffinity isolation of urinary 8-hydroxy-2′-deoxyguanosine and 8-hydroxyguanine and quantitation of 8-hydroxy-2′-deoxyguanosine in DNA by polyclonal antibodies. Carcinogenesis 12:865-871 (1991).
51. Bruze M, Emmett EA, Creasey J, Strickland PT. Cyclobutadithymidine induction by solar-simulating UV radiation in human skin. II: Individual responses. J Invest Dermatol 93:341-344 (1989).
52. Phillips DH, Hewer A, Grover PL, Jass JR. An aromatic DNA adduct in colonic mucosa from patients with colorectal cancer. In: Methods for Detecting DNA Damaging Agents in Humans: Applications in Cancer Epidemiology and Prevention (Bartsch H, Hemminki K, O'neill IK, eds). IARC Scientific Publications No 89. Lyon:International Agency for Research on Cancer, 1988;368-371.
53. Phillips DH, Hewer A, Grover PL. Aromatic DNA adducts in human bone marrow and peripheral blood leukocytes. Carcinogenesis 7:2071-2075 (1986).
54. 32P postlabeling. Cancer Res 53:1522-1528 (1993).
55. 32P-postlabeling, in the foregut of patients with familial adenomatous polyposis and in unaffected controls. Carcinogenesis 12:1727-1732 (1991).
56. 32P-postlabeling assay. Carcinogenesis 12:503-508 (1991).
57. 32P-postlabelling analysis of DNA adducts in monocytes of smokers and passive smokers. Int Arch Occup Environ Health 62:299-303 (1990).
58. Randerath K, Miller RH, Mittal D, Randerath E. Monitoring human exposure to carcinogens by ultrasensitive postlabelling assays: application to unidentified genotoxicants. In: Methods for Detecting DNA Damaging Agents in Humans: Applications in Cancer Epidemiology and Prevention (Bartsch H, Hemminki K, O'neill IK, eds). IARC Scientific Publications No 89. Lyon:International Agency for Research on Cancer, 1988;361-367.
59. Hemminki K, Perera FP, Phillips DH, Randerath K, Reddy MV, Santella RM. Aromatic DNA adducts in white blood cells of foundry workers. In: Methods for Detecting DNA Damaging Agents in Humans: Applications in Cancer Epidemiology and Prevention (Bartsch H, Hemminki K, O'neill IK, eds). IARC Scientific Publications No 89. Lyon:International Agency for Research on Cancer, 1988;190-195.
60. Hemminki K, Randerach K, Reddy MV, Putman KL, Santella RM, Perera FP, Young TL, Phillips DH, Hewer A, Savela K. Postlabeling and immunoassay analysis of polycyclic aromatic hydrocarbons-adducts of deoxyribonucleic acid in white blood cells of foundry workers. Scand J Work Environ Health 16:158-162 (1990).
61. van Schooten FJ, van Leeuwen FE, Hillebrand MJ, de Rijke ME, Hart AA, van Veen HG, Oosterink S, Kriek E. Determination of benzo[a]pyrene diol epoxide-DNA adducts in white blood cell DNA from coke-oven workers: the impact of smoking. J Natl Cancer Inst 82:927-933 (1990).
62. Lewtas J, Mumford J, Everson RB, Hulka B, Wilcosky T, Kozumbo W, Thompson C, George M, Dobiäs L, Sram R. Comparison of DNA adducts from exposure to complex mixtures in various human tissues and experimental systems. Environ Health Perspect 99:89-97 (1993).
63. 32P-postlabeling and by enzyme-linked immunosorbent assay (ELISA). Environ Health Perspect 99:307-309 (1993).
64. 32P-postlabeling analysis. Carcinogenesis 11:205-211 (1990).
65. Schoket B, Horkay I, Kösa A, Paldeak L, Hewer A, Grover PL, Phillips DH. Formation of DNA adducts in the skin of psoriasis patients, in human skin in organ culture, and in mouse skin and lung following topical application of coal-tar and juniper tar. J Invest Dermatol 94:241-246 (1990).
66. 32P-postlabeling analysis. Mutat Res 202:85-91 (1988).
67. Bodell WJ, Pongracz K, Kaur S, Burlingame AL, Liu SF, Rappaport SM. Investigation of styrene oxide-DNA adducts and their detection in workers exposed to styrene. Prog Clin Biol Res 340C:271-282 (1990).
68. 7-guanine in human urine obtained in the Gambia, West Africa. Cancer Epidemiol Biom Prev 1:221-227 (1992).
69. 1, its metabolites, and DNA adducts by synchronous fluorescence spectrophotometry. Cancer Res 46:3249-3253 (1986).
70. Weston A, Shields PG, Bowman ED. Isolation of polycyclic aromatic hydrocarbon-DNA adducts from human lung. In: Polycyclic Aromatic Compounds (Garrigues P, Lamotte M, eds). Paris:Gordon and Breach, 1993;937-944.
71. Weston A, Bowman ED. Fluorescence detection of benzo[a]pyrene-DNA adducts in human lung. Carcinogenesis 12:1445-1449 (1991).
72. Weston A, Rowe ML, Manchester DK, Farmer PB, Mann DL, Harris CC. Fluorescence and mass spectral evidence for the formation of benzo[a]pyrene anti-diol-epoxide-DNA and -hemoglobin adducts in humans. Carcinogenesis 10:251-257 (1989).
73. Harris CC, Vahakangas K, Newman MJ, Trivers GE, Shamsuddin A, Sinopoli N, Mann DL, Wright WE. Detection of benzo[a]pyrene diol epoxide-DNA adducts in peripheral blood lymphocytes and antibodies to the adducts in serum from coke oven workers. Proc Natl Acad Sci USA 82:6672-6676 (1985).
74. Lin D, Lay JO, Bryant MS, Malaveille C, Friesen M, Bartsch H, Lang NP, Kadlubar FF. Analysis of 4-aminobiphenyl-DNA in human urinary bladder and lung by alkaline hydrolysis and negative ion gas chromatography/mass spectrometry. Environ Health Perspect 102:11-16 (1993).
75. Farmer PB. Analytical approaches for the determination of protein-carcinogen adducts using mass spectrometry. In: Molecular Dosimetry and Human Cancer (Groopman JD, ed). Boca Raton, FL:CRC Press, 1991;189-210.
76. Prevost V, Shuker DE, Friesen MD, Eberle G, Rajewsky MF, Bartsch H. Immunoaffinity purification and gas chromatography-mass spectrometric quantification of 3-alkyladenines in urine: metabolism studies and basal excretion levels in man. Carcinogenesis 14:199-204 (1993).
77. Shuker DE. Nucleic acid-carcinogen adducts in human dosimetry. Arch Toxicol Suppl 13:55-65 (1989).
78. Farmer PB, Bailey E, Green JA, Leung CS, Manson MM. Biomonitoring of human exposure to alkylating agents by measurement of adducts to haemoglobin or DNA. In: Relevance to Human Cancer of N-Nitroso Compounds, Tobacco Smoke and Mycotoxins (O'Neill IK, Chen J, Bartsch H, eds). IARC Scientific Publications No 105. Lyon:International Agency for Research on Cancer, 1991:71-77.
79. Foiles PG, Akerkar SA, Carmella SG, Kagan M, Stoner GD, Resau JH, Hecht SS. Mass spectrometric analysis of tobacco-specific nitrosamine-DNA adducts in smokers and nonsmokers. Chem Res Toxicol 4:364-368 (1991).
80. Poirier MC, Reed E, Litterst CL, Katz D, Gupta-Burt S. Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients. Cancer Res 52:149-153 (1992).
81. Reed E, Parker RJ, Gill I, Bicher A, Dabholkar M, Vionnet JA, Bostick-Bruton F, Tarone R, Muggia FM. Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies. Cancer Res 53:3694-3699 (1993).
82. Shigenaga MK, Gimeno CJ, Ames BN. Urinary 8-hydroxy-2′-deoxyguanosine as a biological marker of in vivo oxidative DNA damage. Proc Natl Acad Sci USA 86:9697-9701 (1989).
83. Kiyosawa H, Suko M, Okudaira H, Murata K, Miyamoto T, Chung MH, Kasai H, Nishimura S. Cigarette smoking induces formation of 8-hydroxydeoxyguanosine, one of the oxidative DNA damages in human peripheral leukocytes. Free Radic Res Commun 11:23-27 (1990).
84. Hemminki K, Grzybowska E, Chorazy M, Twardowska-Saucha K, Sroczynski JW, Putman KL, Randerath K, Phillips DH, Hewer A, Santella RM et al. DNA adducts in human environmentally exposed to aromatic compounds in an industrial area of Poland. Carcinogenesis 11:1229-1231 (1990).
85. Ovrebo S, Haugen A, Phillips DH, Hewer A. Detection of polycyclic aromatic hydrocarbon-DNA adducts in white blood cells from coke oven workers: correlation with job categories. Cancer Res 52:1510-1514 (1992).
86. Poirier MC, Schoket B, Weston A, Rothman N, Scott B, Deeter DP. Blood cell polycyclic aromatic hydrocarbon (PAH)-DNA adducts and PAH urinary metabolites in soldiers exposed to Kuwaiti oil well fires [Abstract]. Proc Am Assoc Cancer Res 35:95 (1994).
87. Grzybowska E, Hemminki K, Szeliga J, Chorazy M. Seasonal variation of aromatic DNA adducts in human lymphocytes and granulocytes. Carcinogenesis 14:2523-2526 (1993).
88. Rothman N, Correa-Villasenor A, Ford DP, Poirier MC, Haas R, Hansen JA, O'Toole T, Strickland PT. Contribution of occupation and diet to white blood cell polycyclic aromatic hydrocarbon-DNA adducts in wildland firefighters Cancer Epidemiol Biomarkers Prev 2:341-348 (1993).
89. Groopman JD, Zhu JQ, Donahue PR, Pikul A, Zhang LS, Chen JS, Wogan GN. Molecular dosimetry of urinary aflatoxin-DNA adducts in people living in Guangxi Autonomous Region, People's Republic of China. Cancer Res 52:45-52 (1992).
90. Groopman JD, Trudel LJ, Donahue PR, Marshak-Rothstein A, Wogan GN. High-affinity monoclonal antibodies for aflatoxins and their application to solid-phase immunoassays. Proc Natl Acad Sci USA 81:7728-7731 (1984).
91. Groopman JD, Sabbioni G, Wild CP. Molecular dosimetry of human aflatoxin exposures. In: Molecular Dosimetry and Human Cancer (Groopman JD, ed). Boca Raton, FL:CRC Press, 1991;303-324.
92. Reed E, Yuspa SH, Zwelling LA, Ozols RF, Poirier MC. Quantitation of cisplatin-DNA intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy. J Clin Invest 77:545-550 (1986).
93. Fichtinger-Schepman AM, van Oosterom AT, Lohman PH, Berends F. cis-Diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II). Cancer Res 47:3000-3004 (1987).
94. 6-methylguanine in human DNA after therapeutic exposure to methylating agents and its relationship with biological effects. Environ Health Perspect 99:143-147 (1993).
95. Ross RK, Yuan JM, Yu MC, Wogan GN, Qian GS, Tu JT, Groopman JD, Gao YT, Henderson BE. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 339:943-946 (1992).
96. Qian GS, Yu MC, Ross R, Yuan JM, Gao YT, Henderson B, Wogan GN, Groopman JD. Urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biom Prev 3:3-10 (1994).
97. Schulte PA, Perera FP. Molecular Epidemiology: "Principles and Practices." Boca Raton, FL:CRC Press, 1993.